The company Kling Biotherapeutics B.V is enrolling patients into the clinical trial investigating Study of KBA1412 in Participants With Advanced Solid Malignant Tumors.
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
The trial is designed to enroll male and female 18 Years and older and is being conducted in the University Hospital Ghent, Ghent, Belgium.
The study start date is August 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05501821.